Sunshine Biopharma Inc. (SBFM.OB), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced that its operations are unaffected by the recent Supreme Court ruling on patentability of Human Genes.
Sunshine Biopharma said its anticancer drug development program is not dependent on and does not utilize human genes. Sunshine Biopharma had previously reported that Adva-27a is capable of effectively killing aggressive or multidrug resistant cancer cells including Breast Cancer cells (MCF-7/MDR), Small-Cell Lung Cancer cells (H69AR), Uterine Sarcoma cells (MES-SA/Dx5), and Pancreatic Cancer cells (Panc-1).
"Sunshine Biopharma is not in the business of patenting human genes or copies thereof, such as cDNA. We patent small molecules for use as chemotherapeutics in the treatment of cancer," said Steve Slilaty, CEO of Sunshine Biopharma.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.